Table 1. Baseline clinical characteristics.
| Characteristic | No. (%)* | DFS | OS | ||
|---|---|---|---|---|---|
| Log-rank | p-value | Log-rank | p-value | ||
| Histology | 150 | 0.001 | 0.981 | 0.652 | 0.419 |
| IDC | 148 (98.7) | ||||
| Others | 2 (3.3) | ||||
| Age (yr) | 150 | 4.327 | 0.038 | 2.908 | 0.088 |
| <45 | 48 (32.0) | ||||
| ≥45 | 102 (68.0) | ||||
| Histologic grade | 150 | 8.567 | 0.014 | 6.259 | 0.043 |
| I | 3 (2.0) | ||||
| II | 51 (34.0) | ||||
| III | 96 (64.0) | ||||
| T staging | 150 | 11.667 | 0.022 | 3.347 | 0.501 |
| Tis-1 | 39 (26.0) | ||||
| T2 | 84 (56.0) | ||||
| T3 | 19 (12.7) | ||||
| T4 | 11 (5.3) | ||||
| Nodal status | 150 | 20.582 | <0.001 | 22.502 | <0.001 |
| N0 | 61 (40.7) | ||||
| N1 | 38 (25.3) | ||||
| N2 | 31 (20.1) | ||||
| N3 | 20 (13.3) | ||||
| Metastasis | 150 | 0.503 | 0.478 | 0.391 | 0.532 |
| M0 | 145 (96.1) | ||||
| M1 | 5 (3.9) | ||||
| Menopause | 150 | 0.011 | 0.916 | 0.708 | 0.400 |
| Yes | 79 (52.7) | ||||
| No | 71 (47.3) | ||||
| ER status | 149 | 0.594 | 0.441 | 1.066 | 0.302 |
| Positive | 97 (65.3) | ||||
| Negative | 52 (34.7) | ||||
| PR status | 149 | 7.176 | 0.007 | 4.252 | 0.039 |
| Positive | 53 (35.5) | ||||
| Negative | 96 (64.5) | ||||
| HER2 status | 149 | 5.610 | 0.132 | 7.586 | 0.055 |
| Positive | 22 (17.1) | ||||
| Negative | 97 (75.2) | ||||
| Distant metastasis | 150 | 66.310 | <0.001 | 156.664 | <0.001 |
| Yes | 51 (33.4) | ||||
| No | 99 (66.6) | ||||
| Recurrence | 150 | 16.707 | <0.001 | 38.615 | <0.001 |
| Yes | 11 (8.3) | ||||
| No | 139 (91.7) | ||||
DFS=disease-free survival; OS=overall survival; IDC=invasive ductal carcinoma; ER=estrogen receptor; PR=progesterone receptor; HER2=human epithelial growth factor receptor 2.
*Number differences reflect missing data.